-
my country's first third-generation BCR-ABL inhibitor oribatinib was launched, hitting CML resistance!
Time of Update: 2022-01-10
It is understood that oribatinib has been approved by the National Medical Products Administration (NMPA) of China on November 25 for the treatment of resistance to any tyrosine kinase inhibitor (TKI), and uses fully validated The detection method diagnoses adult patients with chronic myeloid leukemia (CML) with T315I mutation in the chronic phase (CP) or accelerated phase (AP) .
-
Innovent and Ascent Pharmaceuticals jointly announced that China's first third-generation BCR-ABL
Time of Update: 2022-01-02
pharmaceutical companies, today announced that the original class of drugs Ao Leiba erlotinib tablets (Olverembatinib, trade name: resistant gram ® ) formally approved by China's State Drug Administration (NMPA) approved for the treatment of any tyrosine kinase inhibitors Drug resistance (TKI), and the use of fully validated detection methods to diagnose chronic phase (CP) or accelerated phase (AP) adult chronic myeloid leukemia (CML) patients with T315I mutation .
-
The first three-generation BCR-ABL TKI in China!
Time of Update: 2021-12-04
After the first-generation BCR-ABL inhibitor Imatinib (Gleevec) and several subsequent second-generation drugs were launched, the clinical treatment of CML has made great progress and patients can achieve long-term survival .
The first indication developed by oribatinib is Bcr-Abl T315I mutant CML.
-
Ascent Pharmaceuticals Oribatinib is planned to be included in the breakthrough therapy category, and it is the first three-generation BCR-ABL inhibitor in China
Time of Update: 2021-07-14
A clinical-stage R&D enterprise dedicated to the development of innovative drugs in the treatment of tumors, hepatitis B and aging-related diseases, Yasheng Pharmaceutical announced today that th
-
Ascent Pharma's third-generation BCR-ABL inhibitor plans to be included in breakthrough treatment products
Time of Update: 2021-04-28
Source: Guanlan PharmaceuticalAccording to the latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China, Yasheng Pharmaceutical's wholly-owned subsidiary, Shunjian Biologics, a new class 1 drug, nectinib tablets (HQP1351, also known as oribatinib), will be included in the breakthrough treatment Variety, the proposed indication is: for the treatment of chronic myelogenous leukemia (CML) patients who are resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors.
-
Ascent Pharmaceuticals Nectinib is included in the proposed breakthrough treatment, and it is China's first BCR-ABL targeted CML drug
Time of Update: 2021-04-27
Screenshot source: CDE official website HQP1351 is an original Class 1 new drug under research by Ascent Pharmaceuticals, a new third-generation BCR-ABL tyrosine kinase inhibitor (Tyrosine Kinase Inhibitor, TKI), used to treat first- and second-generation TKI resistance Chronic Myelogenous Leukemia (CML), especially for CML patients with T315I mutation, has a good effect.
-
Ascent Pharmaceuticals Nectinib is included in the proposed breakthrough treatment, and it is China's first BCR-ABL targeted CML drug
Time of Update: 2021-03-27
Screenshot source: CDE official website HQP1351 is an original Class 1 new drug under research by Ascent Pharmaceuticals, a new third-generation BCR-ABL tyrosine kinase inhibitor (Tyrosine Kinase Inhibitor, TKI), used to treat first- and second-generation TKI resistance Chronic Myelogenous Leukemia (CML), especially for CML patients with T315I mutation, has a good effect.
-
Third-generation BCR-ABL inhibitor Assin Pharmaceutical Leukemia candidates were included in the priority review.
Time of Update: 2020-10-27
It's worth noting that, according to the press release, the inclusion of the drug in the priority review not only means that Arribatini is expected to become Chinese mainland's first third-generation BCR-ABL inhibitor, but also means that Asaan Pharma will welcome the first new drug to be approved for sale.
-
Flumatinib, the first second generation BCR ABL tyrosine kinase inhibitor in China, is on the market
Time of Update: 2019-11-27
Flumatinib (trade name: hausen Xinfu), a new anti-tumor class 1 drug independently developed by hausen, is intended to be used to treat Philadelphia chromosome positive chronic myeloid leukemia (Ph +